Nitrase Therapeutics
Henrijette is Managing Partner at Sofinnova Partners. She joined as Partner in 2014 from Novo Seeds (part of Novo Holdings) where she was involved in the establishment of the group in 2007. While at Novo Seeds Henrijette was instrumental in the creation, financing and building of companies such as Orphazyme (ORPHA.CO), Avilex Pharma, EpiTherapeutics (sold to Gilead) and Lysogene (LYS.PA). Henrijette is a scientist by training and started her career at Novo Nordisk conducting her PhD in the area of obesity and GH signalling. Before joining Sunstone Capital in 2004, Henrijette was a postdoctoral fellow at the MIT Center for Cancer Research (MA). Henrijette invested in and is or has been a board member of Asceneuron (CH), Delinia (sold to Celgene for up to $775 million), iOmx, Nodthera, Comet, and Twentyeight-Seven.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).